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Abstract
Background Eculizumab is approved for atypical hemo-
lytic uremic syndrome (aHUS). Guidelines discuss the
importance of prompt treatment. We report a post hoc
analysis investigating the effect of baseline factors,
including patient characteristics and time from the latest
aHUS manifestation to eculizumab initiation, on change
from baseline in estimated glomerular filtration rate
(eGFR) and other outcomes.
Methods Data were pooled from four phase 2, open-label,
single-arm, prospective clinical studies of eculizumab for
patients with aHUS. Multivariate regressions identified
predictors of eGFR change from baseline. The proportion
of patients achieving sustained eGFR increase (defined:
C15 ml/min/1.73 m2 for C28 days) and platelet count
normalization were evaluated 1 year post-treatment.
Baseline characteristics and eGFR outcomes were
summarized by time to treatment from last aHUS mani-
festation [B7 days (n = 21) versus[7 days (n = 76)].
Results Baseline eGFR were similar between groups.
Multivariate regression analysis demonstrated time from
aHUS manifestation to eculizumab treatment, age, baseline
lactate dehydrogenase (LDH) and baseline hemoglobin
were independently predictive of eGFR change from
baseline. Mean eGFR change from baseline at 1 year was
significantly higher in patients treated in B7 days than
[7 days (57 vs. 23 ml/min/1.73 m2, p = 0.0098). After
1 year, 17/21 and 36/76 patients in the B7 and [7 day
groups, respectively, achieved a sustained increase in
eGFR. Mean time to platelet count normalization was
similar between groups.
Conclusions Younger age, higher baseline LDH and
lower baseline hemoglobin were associated with greater
eGFR improvements. Early eculizumab initiation led to
improved renal recovery, demonstrating the importance of
rapid diagnosis and treatment of patients with aHUS.
Keywords Atypical hemolytic uremic syndrome 
Chronic kidney disease  Eculizumab  Thrombocytopenia 
Thrombotic microangiopathy
Introduction
Atypical hemolytic uremic syndrome (aHUS) is a life-
threatening condition [1] caused by uncontrolled activation
of the alternative complement pathway that results in
damage to endothelial cells and systemic thrombotic
microangiopathy (TMA) [2–4]. Approximately 60 % of
patients with aHUS have an identified complement regu-
latory protein dysfunction or mutation in a complement
gene [3, 5]. Progression of aHUS can be rapid and severe,
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and symptoms are characterized by hemolytic anemia,
thrombocytopenia and organ damage [3]. The disease
predominantly affects the renal vasculature, but ongoing
TMA can also impair other organs including the brain,
heart, intestines, pancreas, and lungs [2, 3]. Prior to the
availability of eculizumab, over 50 % of patients with
aHUS died, required dialysis or developed permanent
kidney damage within the first year after diagnosis [3].
The rapid progression of TMA, associated with poten-
tially irreversible damage to organs in patients with aHUS,
indicates a need for urgent treatment. TMAmay lead to acute
renal dysfunction in early disease, and evidence suggests
acute kidney injury (AKI) and chronic kidney disease (CKD)
are closely interrelated, with each being a risk factor for the
other [6]. Plasma exchange/plasma infusion (PE/PI) has been
used to manage aHUS, but there is no prospective clinical
trial evidence showing its efficacy. PE/PI does not resolve
the underlying disease, and often fails to prevent progression
to end-stage renal disease [1]. Persistence of an inflammatory
environment can impair kidney regeneration and further
promote the development of CKD [7] in both native and
transplanted kidneys [1, 3, 8].
Eculizumab is a recombinant humanized monoclonal
antibody that blocks the cleavage of C5, preventing for-
mation of the proinflammatory peptide C5a and the cyto-
toxic membrane attack complex C5b-9 [2]. Multiple cases
and four published prospective clinical studies conducted
in patients with aHUS have shown efficacy of eculizumab
in aHUS [1, 9, 10], which has led to its approval for the
treatment of this disorder. The first trial enrolled patients
with progressive TMA (n = 17) and the second enrolled
patients receiving long-term PE/PI (n = 20). Both trials
met their primary endpoints at 26 weeks: first trial, platelet
count normalization, and second trial, TMA event-free
status (defined as no decrease in the platelet count of
[25 %, no PE/PI, and no initiation of dialysis). At the
1-year data cutoff, the mean increase in platelet count from
baseline was 91 9 109/l [95 % confidence interval (CI)
67–116] in the first trial; TMA event–free status for
C12 weeks was achieved in 85 % of patients in the second
trial. Both trials achieved normalization of platelet count
and lactate dehydrogenase (LDH) levels (88 and 90 %
respectively) [10]. A recent follow-up has shown benefits
are maintained at 2 years, with median eculizumab treat-
ment of 100 and 114 weeks in the two trials, respectively
[11]. The third trial enrolled 41 adult patients, while the
fourth enrolled 22 patients aged 1 month to \18 years.
Initial treatment was for 26 weeks with the possibility of
continuing eculizumab treatment in a long-term follow-up.
In the adult study, 73 % of patients met the primary end-
point, defined as normalization of platelets and LDH and
\25 % increase from baseline in serum creatinine levels at
26 weeks [1]. Results from the pediatric study showed
64 % of patients met the primary endpoint, defined as
normalization of platelets and LDH and C25 % improve-
ment from baseline in serum creatinine levels at 26 weeks
[1].
Guidelines recommend children and adults with a clinically
definitive aHUS diagnosis be treated with eculizumab ideally
within 24 h [9, 12]. It has also been suggested to consider no
more than 5 daily plasma exchanges where further investiga-
tions are required to confirm aHUS diagnosis. A lack of nor-
malizationofplatelet count andLDHor improvement in serum
creatinine levels within this time is an additional indicator for
the switch to eculizumab [9, 12].Therefore, it is reasonable that
patients presenting with TMA as a consequence of aHUS start
eculizumab in less than a week.
While the timing of therapy initiation for aHUS has
been investigated in small patient cohorts, it remains to be
studied in a substantive population [9]. We therefore car-
ried out a post hoc analysis of pooled data from four
clinical trials of eculizumab to evaluate the impact of time
from onset of last aHUS manifestation to treatment with
eculizumab, as well as other factors, on renal and hema-
tological outcomes in patients with aHUS.
Methods
Data were pooled from the four previously described phase
2, open-label, single-arm, prospective clinical studies
which enrolled patients aged 1 month to 80 years [1, 10].
Inclusion required a documented date of onset of symp-
toms of TMA and a baseline estimated glomerular filtration
rate (eGFR) of \90 ml/min/1.73 m2. All patients were
receiving eculizumab for the first time. In this pooled
analysis, three major clinical outcomes were considered:
(1) eGFR change from baseline at 1 week and monthly
over 1 year, (2) proportion of patients achieving a sus-
tained eGFR increase of C15 ml/min/1.73 m2 (improve-
ment maintained for at least 28 days) from baseline to
1 year of follow-up, and (3) time to platelet count nor-
malization (C150 9 109/l). Baseline was defined as: at
enrollment prior to first eculizumab dose. It should be
noted that when patients were on dialysis, their eGFR was
imputed to 10 ml/min/1.73 m2.
In order to explore in a clinically relevant and
dichotomous way the effect of time from the latest aHUS
manifestation to initiation of eculizumab treatment, results
were stratified according to whether patients had started
eculizumab treatment B7 or[7 days after the onset of the
latest aHUS manifestation (herein referred to as time to
treatment). Baseline characteristics were compared
between the B7 and[7 day groups using the Wilcoxon
rank-sum test for continuous variables and the Fisher exact
test for categorical variables. The difference between the
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B7 and[7 day groups in time to platelet count normal-
ization was tested using the two-group t test. To test the
difference between the two groups (B7 and[7 day) on the
proportion of patients achieving a sustained eGFR increase
of C15 ml/min/1.73 m2, Fisher’s exact test was performed
for each visit.
Multivariate regressions using repeated measures anal-
ysis were performed to identify predictors of change in
eGFR from baseline through 1 year. Baseline eGFR and
trial visit (scheduled post-dose visits in months) were
always kept in the model as the dependent variable was
change from baseline in eGFR and the analysis was a
repeated measures analysis over post-dose visits up to
12 months. Ten other baseline variables or patient char-
acteristics were tested, including six categorical variables:
age group (\18 vs. C18 years), mutation (complement
factor H [CFH] mutation, non-CFH mutation, and no
mutation), history of TMA manifestation (single vs. mul-
tiple), transplant history (yes vs. no), dialysis at baseline
(yes vs. no), PE/PI at baseline (yes vs. no), as well as four
continuous variables: time to treatment, baseline platelet
count, baseline LDH, and baseline hemoglobin. Selection
of variables was performed using a forward stepwise pro-
cedure to identify the main effects and their interaction
terms for inclusion in the final model. In order to test the
effect of time to treatment as both a continuous and a
Table 1 Baseline demographics and disease characteristics of the 97 patients with aHUS included in the pooled analysis
Characteristic Time to treatment p*
B 7 days, n = 21 [7 days, n = 76 All, n = 97
Median age, years (range) 30 (0–69) 29 (0–80) 29 (0–80)
Age group in years, n (%)
\18 10 (48) 15 (20) 25 (26) 0.029
C18 11 (52) 61 (80) 72 (74)
Female gender, n (%) 11 (52) 49 (64) 60 (62) 0.323
Complement mutation or autoantibody, n (%)
Any mutation or autoantibody 9 (43) 48 (63) 57 (59) 0.133
CFH mutation 5 (24) 19 (25) 24 (25)
No complement mutation or autoantibody, n (%) 12 (57) 28 (37) 40 (41)
Median time from last aHUS manifestation to
eculizumab treatment, months (range)
0.13 (0.03–0.20) 1.02 (0.23–47.40) 0.75 (0.03–47.40) –
Median number of TMA events, n (range) 1 (1–6) 1 (1–9) 1 (1–9) 0.421
Receiving PE/PI at baseline, n (%) 11 (52) 60 (79) 71 (73) 0.001
Median PE/PI duration during last aHUS
manifestation prior to first dose, months (range)
0.10 (0.03–0.20) 0.67 (0.03–46.46) 0.49 (0.03–46.46) \0.001§
Dialysis at baseline, n (%) 12 (57) 31 (41) 43 (44) 0.219
Median dialysis duration during last aHUS
manifestation prior to first dose, months (range)
0.05 (0.03–0.20) 0.39 (0.03–34.85) 0.30 (0.03–34.85) 0.007
History of kidney transplantation, n (%) 7 (33) 19 (25) 26 (27) 0.578
Median baseline platelet count 9 109/l (range) 81.5 (18.0–193.0) 133.5 (16.0–420.5) 127.5 (16.0–420.5) 0.002§
Platelet count\150 9 109/l, n (%) 19 (90) 45 (59) 64 (66) 0.008
Median hemoglobin, mg/dl (range) n = 18
84.0 (41.0–117.0)
n = 71
92.0 (54.0–131.0)
n = 89
89.0 (41.0–131.0)
0.122§
Median LDH, U/l (range) 669.1 (131.0–7164.0) 297.5 (134.0–3682.0) 343.0 (131.0–7164.0) \0.001§
Median creatinine, lmol/l (range) n = 20
214.0 (112.0–1007.8)
n = 74
243.1 (28.0–1169.6)
n = 94
238.7 (28.0–1169.6)
0.708§
Median baseline eGFR, ml/min/1.73 m2 (range)a 11.0 (5.6–53.2) 16.0 (7.3–76.1) 15.9 (5.6–76.1) 0.299§
aHUS atypical hemolytic uremic syndrome, CFH complement factor H, eGFR estimated glomerular filtration rate, LDH lactate dehydrogenase,
PE/PI plasma exchange/plasma infusion, TMA thrombotic microangiopathy
* Comparison between B7 and[7 day groups
 p values calculated using the Fisher exact test
§ p values calculated using the Wilcoxon rank-sum test
a eGFR for patients on dialysis was imputed to 10 ml/min/1.73 m2
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categorical variable, after the final model was identified
(including time to treatment), it was repeated replacing
continuous time to treatment with categorical time to
treatment (B7 vs.[7 days).
The raw mean changes in eGFR from baseline over time
up to 12 months are presented for the two dichotomized
time to treatment groups (B7 and[7 days). To evaluate the
differences in eGFR change from baseline between the two
groups not controlling for other factors, a two-group t test
was performed at each visit.
Results
Of the original 100 patients in the intent-to-treat popula-
tion, 97 were eligible for the pooled analysis. Three
patients were not eligible because they either lacked a
recorded date for onset of signs of aHUS or had a baseline
eGFR[ 90 ml/min/1.73 m2. Sixty-eight (70 %) patients
had data at 12 months follow-up on eculizumab.
Stratification resulted in 21 patients in the group starting
eculizumab at B7 days of presentation of TMA, and 76
patients starting at [7 days of presentation. Baseline
demographics and disease characteristics are shown in
Table 1 (supplementary online Tables 1 and 2 present
baseline demographic data and key characteristics, on an
individual trial basis). Significant differences could be seen
in some baseline parameters between the two groups.Among
patients in the B7 day group there were more patients
\18 years of age, a higher median LDH level, a lower
median platelet count at baseline, a smaller proportion
receiving PE/PI at baseline and a shorter duration of dialysis
compared to the[7 day group. Median eGFR at baseline
was similar: 11 (range 6–53) and 16 (7–76) ml/min/1.73 m2,
in the B7 day vs.[7 day groups, respectively (p = 0.30).
The final model obtained through stepwise forward
variable selection contained significant main effects: time
to treatment, age group, baseline LDH, and hemoglobin.
Significant interaction terms that remained in the final
model were visit (post-dose visits in months) by time to
treatment, visit by age group, visit by baseline LDH, visit
by baseline hemoglobin, and age group by baseline
hemoglobin (Table 2). The final repeated measures analy-
sis model identified above was rerun, replacing the con-
tinuous variable of time to treatment with the categorical
time to treatment (B7 and [7 days). Results of these
models are presented in Table 2.
The final multivariate analysis model showed that time
to treatment as a continuous variable was a significant
factor in determining eGFR change from baseline when
controlling for other factors such as age group, baseline
LDH, hemoglobin, eGFR and post-dose visits. Time to
initiation of eculizumab treatment when dichotomized into
groups for B7 and [7 days was not significant when
controlling for these other factors.
When eGFR change from baseline at each visit was tested
separately between the two groups using a two-group t-test,
patients receiving eculizumabB7 days after first signs of the
last aHUS manifestation showed a significantly (p\ 0.05)
greater mean improvement in eGFR from month 1 onwards.
At 1 year, the eGFR increase from baseline was 57 ml/min/
1.73 m2 in the B7 day group compared with 23 ml/min/
1.73 m2 in the[7 day group (Fig. 1a).
Time to treatment and age group both remained in the
final model as significant factors. A scatter plot of eGFR
change from baseline to 6 months versus time to treatment
showed a similar trend in the relationship between eGFR
change and time to treatment in both children and adults
(Fig. 2a). LDH and hemoglobin were also significant pre-
dictors of eGFR change from baseline, indicating that
patients with higher LDH and/or lower hemoglobin are
expected to have a greater eGFR increase after treatment
(Fig. 2b, c).
Seventeen patients (81 %) in the B7 day group had
achieved a sustained eGFR response (C15 ml/min/1.73 m2
for at least 28 days) at 3 months follow-up. This proportion
Table 2 Repeated measures analysis of eGFR change from baseline to post-treatment through 12 months
Effecta Time to treatment as continuous variable Time to treatment as categorical variable (B7 vs.[7 days)
Coefficient p Coefficient p
Time to treatment (days) -0.03 0.0181 -2.8 0.3569
Age group (adult vs. child) -84.8 0.0061 -88.5 0.0053
Baseline LDH (U/l) 0.01 0.0078 0.01 0.0016
Baseline hemoglobin (g/l) -0.97 0.0002 -1.19 \0.0001
Trial visit – \0.0001 – \0.0001
Baseline eGFR 0.21 0.1964 0.12 0.4539
eGFR estimated glomerular filtration rate, LDH lactate dehydrogenase
a Interaction terms that remain significant in the final model are visit (scheduled post-dose visits in months) by time to treatment, visit by age
group, visit by baseline LDH, visit by baseline hemoglobin, and age group by baseline hemoglobin
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remained stable through 1 year. In contrast, 26 (34 %) and
36 (47 %) patients in the[7 days group achieved a sus-
tained eGFR at 3 months and at 1 year, respectively
(Fig. 1b). The proportion achieving a sustained eGFR
response (C15 ml/min/1.73 m2) was significantly higher
(p\ 0.05) for the B7 day group compared to the[7 day
group at all visits based on Fisher’s exact test.
Of the pooled cohort of 97 patients, 64 had an abnormal
platelet count at baseline. Platelet counts normalized in 60
of these patients, 18 (86 %) in the B7 day group and 42
(55 %) in the[7 day group. Median time to platelet count
normalization was similar in the two groups (7 vs.
7.5 days), although the range of values in the B7 day
(1–80 days) group was narrower than in the[7 days group
(1–189 days). Corresponding mean (SD) times to platelet
normalization were 14.3 ± 20.3 and 27.8 ± 38.7 days,
respectively (p = 0.083).
Discussion
aHUS is a severe disease with poor outcomes in which
progression can be rapid; prior to the availability of ecu-
lizumab over 50 % of patients with aHUS died, required
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dialysis or developed permanent kidney damage in the first
year after diagnosis [3]. This indicates a need for urgent
treatment of the underlying disease to prevent continuing
organ damage. Observational data show improved recovery
of renal function (decreased serum creatinine levels) in five
patients who received eculizumab therapy within 28 days
of the start of the last aHUS event when compared to 7
patients who received treatment after C28 days [9]. A
significant correlation was also found between time to
initiation of eculizumab treatment after the last presenta-
tion and graft function recovery in 8 patients with kidney
transplantation [9].
This post hoc multivariate analysis of the time from last
aHUS manifestation to treatment suggests that a shorter
time to treatment with eculizumab results in a significantly
better renal outcome for patients with aHUS. This is the
largest group of patients with aHUS in whom the clinical
impact of the timing of eculizumab initiation relative to
presentation with disease has been explored. The analysis
presents data up to 1-year because this was considered
sufficient follow-up to detect differences in outcomes
without excessive loss of patients available for evaluation
over time. Renal outcomes were significantly better in the
group of patients initiating eculizumab treatment in
B7 days of presentation of TMA than in patients initiating
treatment after 7 days. Of interest, the sustained improve-
ment of[15 ml/min/1.73 m2 was achieved more rapidly in
the B7 day group while improvement progressed more
slowly in the[7 day group, indicating the possibility to
also continue eGFR improvement after 6 months of ecu-
lizumab treatment.
Factors other than early treatment initiation with eculi-
zumab that were independently associated with eGFR
outcome were younger age, higher LDH, and lower
hemoglobin. Clinically it can be hypothesized that early
treatment and younger age are suggestive of less renal
damage at treatment initiation and, therefore, possibly
greater potential of recovery of renal function.
Overall, these data support the importance of prompt
treatment of aHUS to optimize recovery of renal function
and to avoid dialysis or transplantation in both adults and
pediatric patients, as reported elsewhere [3, 12, 13]. The
relationship between AKI and CKD is well established [6,
14–17], and as such the avoidance or minimization of AKI
is important for the long-term maintenance of kidney
function without the need for dialysis or transplantation,
including in patients with aHUS [6].
Recent guidelines recommend treating children and
adults with a diagnosis of aHUS with eculizumab within
24 h. In patients where further investigations are required,
and where no significant improvement of both renal and
hematological parameters is observed, eculizumab should
be initiated after no more than 5 plasma exchanges when
aHUS diagnosis has been confirmed [9, 12]. The findings
of this study further support these guidelines.
No significant difference in time to platelet count nor-
malization was shown between patients receiving treatment
in B7 or[7 days, although a trend favoring earlier treat-
ment was evident from mean numbers of days to normal-
ization and ranges of times around median values. In the
original source studies, platelet counts normalized rapidly:
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for example, in the two published trials which enrolled
patients aged C12 years, 53 % of those with abnormal
platelet counts at baseline had normal counts by day 7 [10].
Of note in this context, as illustrated in a case previously
reported by Dorresteijn et al., platelet counts are not always
a reliable marker of improvement in aHUS [18], and TMA
may still progress in patients with normal platelet counts
[19].
Limitations of this study include the non-randomized
study design and the retrospective nature of the analysis,
although the source data were collected prospectively.
Further, it is impossible to know how patients treated in
B7 days would have responded if treatment had been
delayed until [7 days. Also, patients who may have
already been receiving dialysis for an extended period
before starting eculizumab therapy may not have been
expected to show major improvements in eGFR, which
might have resulted in bias favoring the B7 day group. The
median time on dialysis was, however, fairly short
(12 days) in the[7 day group with only two patients on
dialysis for[90 days. It is also not possible to exclude a
tendency for the initiation of eculizumab more rapidly in
patients presenting with more severe symptoms.
In summary, the results of this large pooled analysis
indicate overall that patients with aHUS derive greater and
more sustained eGFR recovery benefit from treatment with
eculizumab when therapy is started earlier. Our data concur
with previous observations and treatment guidelines that
recommend prompt treatment with eculizumab in patients
diagnosed with aHUS.
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